(Q35825613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

main subject

phase III clinical trial

0 references

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Williamson Z Bradford

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Elizabeth A Fagan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ian Glaspole

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Marilyn K Glassberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

David Kardatzke

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Talmadge E King

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Lisa H Lancaster

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Steven D Nathan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Carlos A Pereira

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Steven A Sahn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Jeffrey J Swigris

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Paul W Noble

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

English

0 references

publication date

1 July 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

148

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

196-201

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis

5 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Pirfenidone in idiopathic pulmonary fibrosis

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Worst-rank score analysis with informatively missing observations in clinical trials

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis

15 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4493875

Combining mortality and longitudinal measures in clinical trials

15 November 2018

1 reference

12 December 2020

Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials

1 reference

12 December 2020

Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis

1 reference

12 December 2020

Clinical trials in idiopathic pulmonary fibrosis: a framework for moving forward

1 reference

12 December 2020

The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis

1 reference

12 December 2020

Identifiers

DOI

10.1378/CHEST.14-2817

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

release_q6zdevkegrboxnuuktakkgmqj4

5 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/q6zdevkegrboxnuuktakkgmqj4

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

25856121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25856121%20AND%20SRC:MED&resulttype=core&format=json